Antiosteoclastogenic activity of silicate-based materials antagonizing receptor activator for nuclear factor kappaB ligand-induced osteoclast differentiation of murine marcophages.
BACKGROUND
This study investigated whether calcium silicate cement extract exerted antiosteoclastogenic actions in murine RAW 264.7 macrophages cultured with receptor activator for nuclear factor kappaB (RANKL).


METHODS
The RAW 264.7 macrophage cell was treated with RANKL to osteoclastogenesis. Then, cell viability, cell death, and cathepsin K expression were examined.


RESULTS
The silicon (Si)-inhibited RANKL-induced formation of osteoclasts during the osteoclast differentiation process. It was also found that ≥4 mmol/L Si reduced RANKL-enhanced tartrate-resistant acid phosphatase (TRAP) activity in a dose-dependent manner. Furthermore, Si diminished the expression and secretion of cathepsin K elevated by RANKL and was concurrent with the inhibition of TRAF6 induction and nuclear factor kappaB activation.


CONCLUSIONS
The current report shows that silicate abrogated RANKL-induced osteoclastogenesis by retarding osteoclast differentiation. The Si can modulate every cell through dose-dependent in vitro RANKL-mediated osteoclastogenesis, such as the proliferation and fusion of preosteoclasts, and the function of osteoclasts. Therefore, silicate-based materials may be a potential therapeutic agent targeting osteoclast differentiation in bone defects.
School of Dentistry, Chung Shan Medical University, Taichung City, Taiwan; Department of Dentistry, Chung Shan Medical University Hospital, Taichung City, Taiwan.
Chi-Jr
CJ
Hung
Chia-Tze
CT
Kao
Yi-Jyun
YJ
Chen
Ming-You
MY
Shie
Tsui-Hsien
TH
Huang
D000135:Acid Phosphatase / Q000187:drug effects; D017607:Aluminum Compounds / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D017610:Calcium Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D056657:Cathepsin K / Q000187:drug effects; D018929:Cell Culture Techniques; D016923:Cell Death / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003470:Culture Media; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D007527:Isoenzymes / Q000187:drug effects; D008264:Macrophages / Q000187:drug effects*; D008422:Materials Testing; D051379:Mice; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D010010:Osteoclasts / Q000187:drug effects*; D010087:Oxides / Q000008:administration & dosage / Q000494:pharmacology; D053245:RANK Ligand / Q000037:antagonists & inhibitors*; D012823:Silicate Cement / Q000008:administration & dosage / Q000494:pharmacology*; D017640:Silicates / Q000008:administration & dosage / Q000494:pharmacology*; D012825:Silicon / Q000008:administration & dosage / Q000494:pharmacology; D013054:Spectrophotometry, Atomic / Q000379:methods; D048029:TNF Receptor-Associated Factor 6 / Q000037:antagonists & inhibitors; D000071681:Tartrate-Resistant Acid Phosphatase
D017607:Aluminum Compounds; D017610:Calcium Compounds; D003470:Culture Media; D004338:Drug Combinations; D007527:Isoenzymes; D016328:NF-kappa B; D010087:Oxides; D053245:RANK Ligand; D017640:Silicates; D048029:TNF Receptor-Associated Factor 6; C505689:Tnfsf11 protein, mouse; C086631:mineral trioxide aggregate; D012823:Silicate Cement; D000135:Acid Phosphatase; C000605511:Acp5 protein, mouse; D000071681:Tartrate-Resistant Acid Phosphatase; D056657:Cathepsin K; C534132:Ctsk protein, mouse; C031293:calcium silicate; D012825:Silicon
Calcium silicate cement; RAW 264.7 macrophages; TRAP; mineral trioxide aggregate; receptor activator for nuclear factor kappaB